Targeting of TAK1 in inflammatory disorders and cancer

Hiroaki Sakurai*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

321 Scopus citations

Abstract

The transcription factors nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) are critical regulators of stress responses, immunity, inflammation and cancer. A large variety of cellular stimuli utilize these signaling pathways through a common upstream kinase transforming growth factor-β-activated kinase 1 (TAK1). TAK1 was originally identified as a mitogen-activated kinase kinase kinase (MAP3K) activated by transforming growth factor-β (TGF-β); however, it has been characterized as a key regulator in inflammatory and immune signaling pathways. In addition, microbial proteins and components of host cell signaling scramble for the TAK1 complex in innate immunity. This review highlights the recent advances in the activation mechanisms and physiological functions of TAK1. Research targeting TAK1 raises the potential for new therapeutic options for inflammatory disorders, including cancer.

Original languageEnglish
Pages (from-to)522-530
Number of pages9
JournalTrends in Pharmacological Sciences
Volume33
Issue number10
DOIs
StatePublished - 2012/10

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Targeting of TAK1 in inflammatory disorders and cancer'. Together they form a unique fingerprint.

Cite this